Gothenburg, Sweden– Captario, a Gothenburg-based life sciences decision analytics SaaS platform & services company, has been chosen by Alnylam Pharmaceuticals, a global biopharmaceutical company based in Cambridge, MA, to support their digital transformation journey of optimizing strategic project and portfolio forecasting and modeling. Focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics for genetically-defined diseases, Alnylam looks to manage the complexities of drug development with real-time dynamic modeling and data analytics through use of Captario SUM®.
Peter Ray, Alnylam’s VP Strategy & Portfolio Analytics, is pleased to be adopting Captario’s disruptive technology saying, “We are always looking for new innovations to streamline our decision-making processes and improve our business. This partnership extends the boundaries of current forecasting and valuation methods and enhances transparency and scalability, generating greater portfolio and project insight with less effort.”
“I’m very excited Alnylam has chosen Captario as their preferred long-term collaborative partner for strategic portfolio management” says Johannes Vänngård, CEO of Captario. “It is with great pleasure that we embark on this journey together with Alnylam, and I feel confident that Captario will transcend what is possible to achieve with a portfolio management system.”
For more information, contact Captario at firstname.lastname@example.org.